MX2016007566A - Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4. - Google Patents

Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.

Info

Publication number
MX2016007566A
MX2016007566A MX2016007566A MX2016007566A MX2016007566A MX 2016007566 A MX2016007566 A MX 2016007566A MX 2016007566 A MX2016007566 A MX 2016007566A MX 2016007566 A MX2016007566 A MX 2016007566A MX 2016007566 A MX2016007566 A MX 2016007566A
Authority
MX
Mexico
Prior art keywords
phenoxyethyl
activity
receptor modulators
cyclic amine
amine derivatives
Prior art date
Application number
MX2016007566A
Other languages
English (en)
Inventor
Joseph Fisher Matthew
Lee Kuklish Steven
Allen Schiffler Matthew
Schulenburg York Jeremy
Rudolph Manninen Peter
M Warshawsky Alan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016007566A publication Critical patent/MX2016007566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Abstract

La presente invención proporciona un compuesto de la fórmula (I): en donde X, R, R1, R2, R3, R4, R5, R6, R7, R8 y R9 son como se definen en la presente, o una sal de éste aceptable desde el punto de vista farmacéutico. (ver Fórmula).
MX2016007566A 2013-12-17 2014-12-11 Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4. MX2016007566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361916827P 2013-12-17 2013-12-17
PCT/US2014/069743 WO2015094902A1 (en) 2013-12-17 2014-12-11 Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators

Publications (1)

Publication Number Publication Date
MX2016007566A true MX2016007566A (es) 2016-10-03

Family

ID=52355185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007566A MX2016007566A (es) 2013-12-17 2014-12-11 Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.

Country Status (23)

Country Link
US (1) US9776964B2 (es)
EP (1) EP3083562B1 (es)
JP (1) JP6212644B2 (es)
KR (1) KR101807981B1 (es)
CN (1) CN105793242B (es)
AU (1) AU2014366361B2 (es)
BR (1) BR112016011016A8 (es)
CA (1) CA2928593A1 (es)
CY (1) CY1119583T1 (es)
DK (1) DK3083562T3 (es)
EA (1) EA028921B1 (es)
ES (1) ES2651858T3 (es)
HR (1) HRP20171850T1 (es)
HU (1) HUE035698T2 (es)
LT (1) LT3083562T (es)
ME (1) ME02896B (es)
MX (1) MX2016007566A (es)
NO (1) NO3221486T3 (es)
PL (1) PL3083562T3 (es)
PT (1) PT3083562T (es)
RS (1) RS56615B1 (es)
SI (1) SI3083562T1 (es)
WO (1) WO2015094902A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
CA3060597A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
EA039630B1 (ru) 2017-05-18 2022-02-18 Идорсия Фармасьютиклз Лтд N-замещенные индольные производные
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
CN109970625B (zh) * 2017-12-28 2021-02-26 新发药业有限公司 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法
CN114206866A (zh) * 2019-06-11 2022-03-18 泰昂治疗公司 ***素e2受体4拮抗剂及其用途
EP3885339A1 (en) * 2020-03-27 2021-09-29 Rottapharm Biotech S.r.l. Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
CN112608271A (zh) * 2020-11-26 2021-04-06 安润医药科技（苏州）有限公司 酰胺衍生物及其在制备ep4受体拮抗剂中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
MXPA04005555A (es) 2002-03-18 2005-05-16 Pfizer Prod Inc Procedimientos de tratamiento con agonistas selectivos del receptor ep4.
PL1660491T3 (pl) * 2003-07-28 2009-01-30 Janssen Pharmaceutica Nv Pochodne benzimidazoli, benzotiazoli i benzoksazoli i ich zastosowanie jako modulatorów LT4H
JP4116058B2 (ja) 2003-09-03 2008-07-09 ファイザー株式会社 プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
EA200601830A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
US7968578B2 (en) * 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
BRPI0912778B1 (pt) 2008-05-14 2019-04-30 Astellas Pharma Inc. Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
RU2571816C2 (ru) 2010-02-22 2015-12-20 Раквалиа Фарма Инк. Применение антагонистов рецептора ep4 в лечении il-23-опосредуемых заболеваний
ES2559513T3 (es) * 2011-07-04 2016-02-12 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas del receptor EP4
WO2013004291A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物

Also Published As

Publication number Publication date
SI3083562T1 (sl) 2017-11-30
AU2014366361B2 (en) 2017-04-20
WO2015094902A1 (en) 2015-06-25
CN105793242B (zh) 2018-02-16
CN105793242A (zh) 2016-07-20
EA028921B1 (ru) 2018-01-31
BR112016011016A8 (pt) 2018-01-30
AU2014366361A1 (en) 2016-05-19
CA2928593A1 (en) 2015-06-25
HRP20171850T1 (hr) 2018-01-12
EP3083562B1 (en) 2017-09-27
US20160272585A1 (en) 2016-09-22
KR20160084467A (ko) 2016-07-13
HUE035698T2 (en) 2018-05-28
EA201690894A1 (ru) 2016-10-31
PL3083562T3 (pl) 2018-02-28
US9776964B2 (en) 2017-10-03
LT3083562T (lt) 2018-01-10
DK3083562T3 (da) 2017-11-13
RS56615B1 (sr) 2018-02-28
JP2016540007A (ja) 2016-12-22
KR101807981B1 (ko) 2017-12-11
ES2651858T3 (es) 2018-01-30
JP6212644B2 (ja) 2017-10-11
PT3083562T (pt) 2017-12-13
EP3083562A1 (en) 2016-10-26
CY1119583T1 (el) 2018-03-07
NO3221486T3 (es) 2018-09-08
ME02896B (me) 2018-04-20

Similar Documents

Publication Publication Date Title
MX2016007566A (es) Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
TR201911151T4 (tr) Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
PH12014502788A1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX2016011992A (es) Derivados de piperidina-diona.
MX2015002040A (es) Baricitinib deuterado.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
MY169043A (en) New dihydroquinoline-2-one derivatives
IN2015DN00598A (es)
MX2015006926A (es) Derivados de bencil sulfonamida como moduladores del receptor huerfano relacionado con el receptor retinoide (rorc).
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
JO3318B1 (ar) مثبطات bace
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
GB201209587D0 (en) Therapeutic compounds
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
IN2014DN07996A (es)
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
PH12015501146A1 (en) Hydantoin derivative
MX2015015614A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con el receptor del retinoide (rorc).
IN2015DN02588A (es)